Dr. Lena-Sophie Schütter

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland.

IRUBIS | Innovative Process Analytical Spectroscopy for Biomanufacturing. IRUBIS develops advanced Process Analytical Technology (PAT) tool based on mid-infrared (MIR) spectroscopy to bring intelligence to biopharmaceutical manufacturing. Its flagship product, Monipa, with single-use capabilities delivers inline, real-time concentration data for proteins, excipients, and nucleic acids—empowering faster decision-making, reducing batch loss, and simplifying bioprocess development and scale-up. Read more about our products and innovations at www.irubis.com.

Mevaldi BV was founded in 2020 in the Netherlands, with the scope of investigating, selecting and bring to market new technologies in the field of bio-based chemicals. The founders have in depth knowledge with regards to business development and creating strategic partnerships. We believe that if we want to be successful in the long term, we must create value for our shareholders and society while also protecting the planet and reduce our carbon footprint. We believe in the power of Bio-based “green” chemicals to enhance quality of life for everyone, today and for generations to come. It is this belief that fuels our commitment to use our resources and expertise to contribute to a healthier future for people and the planet. We call it Creating Shared Value and this is how we deliver long-term positive impact for all our stakeholders. At Mevaldi, we use new-age technology to manufacture high performance “green” materials. Our systems approach integrates innovations in chemical catalysis and process development to produce bio-based “green” chemicals. Mevaldi is the first producer of bio-based 3MPD an important ingredient in the production of polyurethanes, coatings, inks and apparel at competitive prices.

inContAlert is a MedTech start-up in the field of incontinence. We are passionate about helping people with bladder dysfunction in their daily life. Our solution consists of a wearable sensor system for measuring the filling level of the urinary bladder, which sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine and empowers patients to live a normal and jaunty life.

SIGNATOPE develops the next generation of protein biomarker assays using a special type of immunoaffinity based mass spectrometry assays. Our tests cover human and all pharmacologically relevant model species.

Mosanna Therapeutics is a clinical-stage biotech company pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) with an easily administered nasal spray. Designed to help restore the body’s natural airway control during sleep, Mosanna’s lead therapy, MOS118, offers a drug-based alternative to traditional mechanical treatments and is currently being evaluated in a Phase 1 clinical trial. Founded in 2022, the company has raised more than $80 million from investors including Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Norwest, Broadview Ventures, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds (HTGF). Mosanna has offices in Redwood City, California and Basel, Switzerland.

IRUBIS | Innovative Process Analytical Spectroscopy for Biomanufacturing. IRUBIS develops advanced Process Analytical Technology (PAT) tool based on mid-infrared (MIR) spectroscopy to bring intelligence to biopharmaceutical manufacturing. Its flagship product, Monipa, with single-use capabilities delivers inline, real-time concentration data for proteins, excipients, and nucleic acids—empowering faster decision-making, reducing batch loss, and simplifying bioprocess development and scale-up. Read more about our products and innovations at www.irubis.com.

Mevaldi BV was founded in 2020 in the Netherlands, with the scope of investigating, selecting and bring to market new technologies in the field of bio-based chemicals. The founders have in depth knowledge with regards to business development and creating strategic partnerships. We believe that if we want to be successful in the long term, we must create value for our shareholders and society while also protecting the planet and reduce our carbon footprint. We believe in the power of Bio-based “green” chemicals to enhance quality of life for everyone, today and for generations to come. It is this belief that fuels our commitment to use our resources and expertise to contribute to a healthier future for people and the planet. We call it Creating Shared Value and this is how we deliver long-term positive impact for all our stakeholders. At Mevaldi, we use new-age technology to manufacture high performance “green” materials. Our systems approach integrates innovations in chemical catalysis and process development to produce bio-based “green” chemicals. Mevaldi is the first producer of bio-based 3MPD an important ingredient in the production of polyurethanes, coatings, inks and apparel at competitive prices.

inContAlert is a MedTech start-up in the field of incontinence. We are passionate about helping people with bladder dysfunction in their daily life. Our solution consists of a wearable sensor system for measuring the filling level of the urinary bladder, which sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine and empowers patients to live a normal and jaunty life.